Cargando…

Challenges and future of HER2-positive gastric cancer therapy

Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced gastric cancer has relatively little progress. With the continuous development of molecularly targeted therapy for tumors, it has been discovered that human epidermal growth factor receptor 2 (HER2) contributes t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Chenzhe, Wang, Xiao, Guo, Jiwu, Yang, Bo, Li, Yumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924067/ https://www.ncbi.nlm.nih.gov/pubmed/36793592 http://dx.doi.org/10.3389/fonc.2023.1080990

Ejemplares similares

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
por: Huang, Le-Tian, et al.
Publicado: (2019)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges
por: Stucci, Luigia Stefania, et al.
Publicado: (2022)

De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy
por: Liu, Jing, et al.
Publicado: (2023)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells
por: Sun, Li-Fei, et al.
Publicado: (2020)

EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives
por: Sun, Keran, et al.
Publicado: (2020)

Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer
por: Nieder, Carsten, et al.
Publicado: (2017)

Hepatocellular Carcinoma Complicated by Echinococcal Cyst: A Case Report
por: Guo, Jiwu, et al.
Publicado: (2022)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment
por: Wang, Shihao, et al.
Publicado: (2023)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
por: Yan, Yan, et al.
Publicado: (2021)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
por: Ran, Ran, et al.
Publicado: (2022)

Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
por: Mao, Xiaoyun, et al.
Publicado: (2022)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
por: Wang, Xinwei, et al.
Publicado: (2022)

Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report
por: Aguilar-Mahecha, Adriana, et al.
Publicado: (2019)

History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
por: Ariga, Shin
Publicado: (2023)

UPS: Opportunities and challenges for gastric cancer treatment
por: Yang, Hang, et al.
Publicado: (2023)

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
por: Marchini, Cristina, et al.
Publicado: (2013)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
por: Umemneku-Chikere, Chinyereugo M., et al.
Publicado: (2022)

Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China
por: Cai, Shuang-Long, et al.
Publicado: (2022)

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
por: Sun, Guang-Yi, et al.
Publicado: (2021)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Accurate preoperative staging and HER2 status prediction of gastric cancer by the deep learning system based on enhanced computed tomography
por: Guan, Xiao, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
por: Yang, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dr6n34rmtdikeoh1a86ppb6cj0